Title of Invention	DIASTEREOSELECTIVE REDUCTIVE AMINATION PROCESS.
Abstract	This invention describes a reductive amination process whereby perfluorinated ketones or ketals are combined with a-aminoesters under basic conditions to form metal carboxylates. Diastereoselective reductions of the metal carboxylates enable access to two diastereomers, depending on the reducing conditions.

Full Text

The present invention relates to Diastereoselective Reductive Amination Process BACKGROUND OF THE INVENTION This invention describes a reductive amination process whereby perfluorinated ketones or ketals are combined with cc-aminoesters under basic conditions to form imine metal carboxylates. Diastereoselective reductions of the imine metal carboxylates enable access to two diastereomers, depending on the reducing conditions. These diastereomers can be further substituted to provide selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and osteoarthritis. The art involved imines of amino esters, where as the instant invention involves imines of carboxylic acid salts. In addition, the previously reported substrates do not contain fluorinated imine substituents. The selectivities obtained under the conditions described herein are much higher than those presented in the art. This invention solves two problems. What is needed in the art is a process for the formation of imines from ketones or ketals bearing fluorines in the alpha position. This is a difficult transformation due to the stability of an initially formed hemi aminal intermediate which is difficult to dehydrate to give the imine. This problem had previously been solved by using strongly acidic solutions and high temperatures, which generally leads to decomposition of the starting materials and low yields of the required imine. The process of this invention uses basic conditions for the imine formation and has a number of advantages, including: the imines are formed under much milder conditions (between 20 and 50°C and the presence of MeO"M+ or M+ efficient recovery (-90%); a wider range of substrates are tolerated by these conditions; and the imine product is a stable carboxylic acid salt which upon reduction can give a corresponding substituted amino acid product. This avoids a potentially problematic ester hydrolysis step which can lead to epimerization of the amino acid stereocenter. Also, by the careful choice of reducing conditions, the two amino acid diastereoisomers can be accessed from the same imine metal carboxylate. SUMMARY OF THE INVENTION By this invention, there are provided processes for the preparation of compounds of structural formulas IA and IB: comprising the steps of: a. Combining a ketone with an Daminoester of formula II in the presence of a base and solvent to form an imine metal carboxylate of formula III, and (Figure Removed) b. Reducing the imine metal carboxylate of formula III to produce a compound formula IA or IB; wherein Rl is C 1.5 alkyl, C3-8 cycloalkyl, aryl or heteroaryl; R2 is Cl-5 alkyl, Cl-5 haloalkyl, C3_g cycloalkyl, arylalkyl, aryl or heteroaryl; R3 Cl-5 alkyl, CM haloalkyl, C3-g cycloalkyl, aryl, heteroaryl, CF3, CHF2,CH2F or M is hydrogen, lithium, sodium, potassium or cesium. DETAILED DESCRIPTION OF THE INVENTION By this invention, there are provided processes for the preparation of compounds of structural formulas IA and IB: comprising the steps of: a. Combining a ketone or ketal with an Uaminoester of formula II in the presence of a base and solvent to form an imine metal carboxylate of formula III, and b. Reducing the imine metal carboxylate of formula III to produce a compound of formula IA or IB; wherein Rl is C 1.5 alkyl, €3-8 cycloalkyl, aryl or heteroaryl; R2 is C 1-5 alkyl, Cj-5 haloalkyl, C3-g cycloalkyl, arylalkyl, aryl or heteroaryl; R3 Ci-5 alkyl, Ci-5 haloalkyl, C3-8 cycloalkyl, aryl, heteroaryl, CFs, CHF2,CH2F or M is hydrogen, lithium, sodium, potassium or cesium. In an embodiment of the invention, R3 is CF3, CHF2,CH2F or C2F5. In an embodiment of the invention, M is potassium. A ketone or ketal is combined with an Ll-aminoester of formula II in the presence of a base and solvent to form an imine metal carboxylate of formula III. In one class of the invention, the base is a metal carbonate or alkoxide, and the solvent is an alcohol, an ether, an ester or an amide. In one subclass of the invention the alcohol is methanol, ethanol, 1-propanol, 2-propanol, trifluoroethanol, butanol, isoamylalcohol, 2- methoxththanol or mixtures thereof. In one subclass of the invention, the ether is tetrahydrofuran (THF), diethyl ether, diisopropyl ether, dibutyl ether, t-butylmethyl ether (TBME), dimethoxyethane, or mixtures thereof. In one subclass of the invention, the ester is ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, ethyl propionate, or mixtures thereof. In one subclass of the invention, the amide is dimethylformamide (DMF), dimethylacetamide (DMAC), l-methyl-2-pyrrolidinone (NMP), 1,3-dimethyl- 3,4,5,6-tetrahydro-2(lH)-pyrimidinone, or mixtures thereof. In one embodiment of the invention, the base is potassium carbonate, potassium methoxide or potassium phosphate and the solvent is methanol. In one class of the invention, this combination is performed at a temperature of about 15°C to about 80°C. In a subclass of the inventibn, the temperature is about 30°C to about 60°C. In one aspect of the invention, the imine metal carboxylate of formula III is not isolated, and the reduction is performed with a metal borohydride prepared in an ether solvent to yield a compound of formula IA. In a class of the invention, the metal borohydride is calcium borohydride, magnesium borohydride, zinc borohydride or zirconium borohydride. In a subclass of the invention, the metal borohydride is zinc borohydride. In a class of the invention, the ether solvent is tetrahydrofuran (THF), diethyl ether, diisopropyl ether, dibutyl ether, t-butylmethyl ether (TBME), dimethoxyethane, ethyleneglycoldimethyl ether or mixtures thereof. In another class of the invention, a cosolvent is added to the ether solvent. In a further class of the invention, the co-solvent is Ci_4 alkyl nitrie or aryl nitrile. In a subclass of the invention, the co-solvent is acetonitrile. In a class of the invention, the volume of co-solvent is 50-95 vol%. In a subclass of the invention, the volume of co-solvent is 85-95 vol%. In a class of the invention, the reduction is performed at a temperature of about 25 °C to about -40 °C to yield a compound of formula IA. In a subclass of the invention, the reduction is performed at a temperature of about 0 °C to about -40 °C to yield a compound of formula LA. In another aspect of the invention the reduction of the metal carboxylate of formula III is performed with a metal borohydride in a solvent to yield a compound of formula IB. In a class of the invention, the metal borohydride is lithium borohydride, sodium borohydride or potassium borohydride. In a subclass of the invention, the metal borohydride is sodium borohydride. In a class of the invention the solvent is tetrahydrofuran. In a class of the invention water is added as a cosolvent in a volume of 1- 10%. In a class of the invention the reduction is performed at a temperature of about 25 °C to about 0 °C. In another aspect of the invention, the reduction is performed with hydrogen and a chiral metal catalyst to yield a compound of formula IB. In one class of the invention, the chiral metal catalyst is derived from an Iridium, Rhodium or Ruthenium complex and a phosphine ligand. In a subclass of the invention, the chiral metal catalyst is (phanephos)Rh(COD)Cl or (i-Pr-ferrolane)Rh(COD)Cl. In another aspect of the invention, the reduction is performed with a boron hydride and a chiral Lewis acid catalyst to yield a compound of formula IB. In one class of the invention, boron hydride is catechol borane. In another aspect of the invention, the chiral Lewis acid catalyst is a C 1.4 alkyl-CBS-oxazaborolidine. In a subclass of the invention, the chiral Lewis acid catalyst is methyl-CBS-oxazaborolidine. By this invention, there are provided processes for the preparation of compounds of structural formulas 1C and ID: comprising the steps of: a. Combining a ketone or ketal with an Qaminoester of formula IV in the presence of a base and solvent to form an imine metal carboxylate of formula V, and b. Reducing the imine metal carboxylate of formula V to produce a compound of formula 1C or ID; wherein Rl is C1-5 alkyl, C3-g cycloalkyl, aryl or heteroaryl; R2 is C1-5 alkyl, Cj-5 haloalkyl, C3-g cycloalkyl, arylalkyl, aryl or heteroaryl; R3 Ci-5 alkyl, Cj-5 haloalkyl, C3-g cycloalkyl, aryl, heteroaryl, CF3, CHF2,CH2F or M is hydrogen, lithium, sodium, potassium or cesium. In an embodiment of the invention, R3 is CF3, CHF2,CH2F or C2FS. In an embodiment of the invention, M is potassium. A ketone or ketal is combined with an L -aminoester of formula IV in the presence of a base and solvent to form an imine metal carboxylate of formula V. In one class of the invention, the base is a metal carbonate or alkoxide, and the solvent is an alcohol, an ether, an ester or an amide. In one subclass of the invention the alcohol is methanol, ethanol, 1-propanol, 2-propanol, trifluoroethanol, butanol, isoamylalcohol, 2- methoxththanol or mixtures thereof. In one subclass of the invention, the ether is tetrahydrofuran (THF), diethyl ether, diisopropyl ether, dibutyl ether, t-butylmethyl ether (TBME), dimethoxyethane, or mixtures thereof. In one subclass of the invention, the ester is ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, ethyl propionate, or mixtures thereof. In one subclass of the invention, the amide is dimethylformamide (DMF), dimethylacetamide (DMAC), l-methyl-2-pyrrolidinone (NMP), 1,3-dimethyl- 3,4,5,6-tetrahydro-2(lH)-pyrimidinone, or mixtures thereof. In one embodiment of the invention, the base is potassium carbonate or potassium methoxide and the solvent is methanol. In one class of the invention, this combination is performed at a temperature of about 15°C to about 80°C. In a subclass of the invention, the temperature is about 30°C to about60°C. In one aspect of the invention, the imine metal carboxylate of formula V is not isolated, and the reduction is performed with a metal borohydride prepared in an ether solvent to yield a compound of formula 1C. In a class of the invention, the metal borohydride is calcium borohydride, magnesium borohydride, zinc borohydride or zirconium borohydride. In a subclass of the invention, the metal borohydride is zinc borohydride. In a class of the invention, the ether solvent is tetrahydrofuran (THF), diethyl ether, diisopropyl ether, dibutyl ether, t-butylmethyl ether (TBME), dimethoxyethane, ethyleneglycoldimethyl ether or mixtures thereof. In another class of the invention, a cosolvent is added to the ether solvent. In a further class of the invention, the co-solvent is Ci-4 alkyl nitric or aryl nitrile. In a subclass of the invention, the co-solvent is acetonitrile. In a class of the invention, the volume of co-solvent is 50-95 vol%. In a subclass of the invention, the volume of co-solvent is 85-95 vol%. In a class of the invention, the reduction is performed at a temperature of about 25 °C to about -40 °C to yield a compound of formula 1C. In a subclass of the invention, the reduction is performed at a temperature of about 0 °C to about -40 °C to yield a compound of formula IA. In another aspect of the invention the reduction of metal carboxylate of formula V is performed with a metal borohydride in a solvent to yield a compound of formula ID. In a class of the invention, the metal borohydride is lithium borohydride, sodium borohydride or potassium borohydride. In a subclass of the invention, the metal borohydride is sodium borohydride. In a class of the invention the solvent is tetrahydrofuran. In a class of the invention water is added as a cosolvent in a volume of 1- 10%. In a class of the invention the reduction is performed at a temperature of about 25 °C to about 0 °C. In another aspect of the invention, the reduction is performed with hydrogen and a chiral metal catalyst to yield a compound of formula ID. In one class of the invention, the chiral metal catalyst is derived from an Iridium, Rhodium or Ruthenium complex and a phosphine ligand. In a subclass of the invention, the chiral metal catalyst is (phanephos)Rh(COD)Cl or (i-Pr-ferrolane)Rh(COD)Cl. In another aspect of the invention, the reduction is performed with a boron hydride and a chiral Lewis acid catalyst to yield a compound of formula ID. In one class of the invention, boron hydride is catechol borane. In another aspect of the invention, the chiral Lewis acid catalyst is a C 1.4 alkyl-CBS-oxazaborolidine. In a subclass of the invention, the chiral Lewis acid catalyst is methyl-CBS-oxazaborolidine. The term "alky!" as used herein shall mean a substituting univalent group derived by conceptual removal of one hydrogen atom from a straight or branched-chain acyclic saturated hydrocarbon (i.e., -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -C(CH3)3? etc.). The term "cycloalkyl" shall mean cyclic rings of alkanes of three to eight total carbon atoms, unless otherwise indicated, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl). As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 12 atoms in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl. In cases where the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic The term "heteroaryl", as used herein, represents a stable monocyclic, bicyclic or tricyclic ring of up to 10 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S. Heteroaryl groups within the scope of this definition include but are not limited to: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydroindolyl, dihydroquinolinyl, methylenedioxybenzene, benzothiazolyl, benzothienyl, quinolinyl, isoquinolinyl, oxazolyl, and tetra-hydroquinoline. In cases where the heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively. If the heteroaryl contains nitrogen atoms, it is understood that the corresponding N-oxides thereof are also encompassed by this definition. As appreciated by those of skill in the art, "halo" or "halogen" as used herein is intended to include chloro, fluoro, bromo and iodo. The' term "keto" means carbonyl (C=O). The term "alkoxy" as used herein means an alkyl portion, where alkyl is as defined above, connected to the remainder of the molecule via an oxygen atom. Examples of alkoxy include methoxy, ethoxy and the like. The term "haloalkyl" means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one to three halogen. Representative examples include, but are not limited to trifluoromethyl, dichloroethyl, and the like. The term "arylalkyl" includes an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above. Examples of arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, and chlorophenylethyl. Examples of alkylaryl include, but are not limited to, toluyl, ethylphenyl, and propylphenyl. , , In the schemes and examples below, various reagent symbols and abbreviations have the following meanings: CH3CN: Acteonitrile DCHA: Dicyclohexylamine HC1: Hydrochloric acid K2CO3: Potassium carbonate MeOH: Methanol TBME: t-Butyl methyl ether THF: Tetrahydrofuran Zn(BH4)2: Zinc Borohydride NaBH4 Sodium Borohydride Schemes 1 and 2 depict the condensation of an alpha-am inoester with a ketone or ketal under basic conditions leads to the formation of a stable isolable imine carboxylate in high yield. Subsequent treatment of the imine under selected reducing conditions provides access to either the syn or anti diasteoisomer of the corresponding substituted amino acid in high yield and selectivity. Thus this methodology can provide easy access to all four diastereoisomers of a substituted amino acid by judicious choice of alpha-aminoeste enantiomer and reducing conditions. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted. 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of L-valine ethyl ester (3.21 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of L-leucine ethyl ester (3.52 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. L-4-fluoro-leucine ethyl ester 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of L-4-fluoroleucine ethyl ester (3.92 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of Lphenylalinine ethyl ester (4.27 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of 25- aminobutanoic acid ethyl ester (2.90 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. 2,2,2-Trifluoroacetophenone (4.24 g, 24.3 mmol) was added to a mixture of L-alinine ethyl ester (2.59 g, 22.1 mmol) and K2CO3 (2.90 g, 20.9 mmol) in MeOH (50 mL). The mixture was warmed to 50 °C for 18h. The mixture was cooled to 20-25 °C, filtered and concentrated. The residue was suspended in TBME (100 ml) and filtered to give the title compound as a white solid. jV-(2,2,2-Trifluoro-l-phenylethylidene)-L-valine potassium salt (50 mg, 0.161 mmol) was combined with sodium borohydride (24.3 mg, 0.642 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2 ml) and the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over NaSO and concentrated to yield the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 65:1. Af-(2,2,2-Trifluoro-l-phenylethylidene)-L-leucine potassium salt (50 mg, 0.154 mmol) was combined with sodium borohydride (23.3 mg, 0.615 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2 ml) and the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over Na2SO4, and concentrated to yield the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 59:1. 4-Fluoro-jV-(2,2,2-Trifluoro-l-phenylethylidene)-L-leucine potassium salt (50 mg, 0.146 mmol) was combined with sodium borohydride (22.0 mg, 0.582 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2ml) and the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over NaiSO and concentrated to yield the title compound as a white solid, indicated a diastereomeric ratio of 71:1. Ar-(2,2,2-Trifluoro-l-phenylethylidene)-L-phenylalinine potassium salt (50 mg, 0.139 mmol) was combined with sodium borohydride (21.1 mg, 0.557 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2 ml) and the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over 2-trifluoro-l-phenylethylidene]amino}butanoic acid potassium salt (50 mg, 0.168 mmol) was combined with sodium borohydride (25.4 mg, 0.673 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2 ml) and,the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over Na2SO4, and concentrated to yield the title compound as a white solid, the product indicated a diastereomeric ratio of 20:1. JV-(2,2,2-Trifluoro-l-phenylethylidene)-L-ethylalinine potassium salt (50 mg, 0.176 mmol) was combined with sodium borohydride (26.7 mg, 0.706 mmol). THF (1.0 ml) and water (40 ul) were added to this mixture and the reaction was stirred at 20-25 °C for Ih. The reaction was quenched with IN NaOH (2 ml) and the aqueous layer extracted once with TBME. The aqueous layer was acidified with IN HC1 (5 ml)) and extracted with TBME (2x10 ml). The organic layer was washed with brine (5 ml), dried over Na2SO4, and concentrated to yield the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 6:1. Zinc (II) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 mg, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to - 40 °C and a suspension of 7V-(2,2,2-trifluoro-l-phenyIethylidene)-L-valine potassium salt (311 mg, 1.0 mmol) in CH3CN (15 ml) and MeOH (1.5 ml) was added. After 3h IN HC1 (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). The organic layers were washed with brine (10 ml), dried overNaaSO filtered and concentrated to give the t i t le compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 33:1. Zinc (!!) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 mg, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to - 40 °C and a suspension of JV-(2,2,2-trifluoro-l-ph.enylethylidene)-L-leucine potassium salt (325 n;:-. 1.0 mmol) in CH3CN (15 ml) and MeOH (1.5 ml) was added. lAfter 3h IN HC1 (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). The organic layers were washed with brine (10 ml), dried overNa2SO4, filtered and concentrated to give the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 18:1. EXAMPLE 15 Zinc (II) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 mg, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to • 40 °C and a suspension of 4-fluoro-Ar-(2,2,2-trifluoro-l-phenylethylidene)-L-leucine potassium salt (343 mg, 1.0 mmol) in CH3CN (15 ml) and MeOH (1.5 ml) was added. After 3h IN HC1 (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). The organic layers were washed with brine (10 ml), dried over NaiSO^ filtered and concentrated to give the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 25:1. Zinc (II) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 mg, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to - 40 °C and a suspension of A^(2,2,2-trifluoro-l-phenylethylidene)-L-phenylalinine potassium salt (359 mg, 1.0 mmol) in CHjCN (15 ml) and MeOH (1.5 ml) was added. After 3h IN HC1 (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). The organic layers were washed with brine (10 ml), dried over Na2SO4, filtered and concentrated to give the title compound as a white solid. |yF NMR of the product indicated a diastereomeric ratio of 17:1. (Figure Removed)inc (II) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 mg, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to - 40 '-C and a suspension of (2S2-{[(/Z)-2,2,2-trifliioro-lphenylethylidene] amino}butanoic acid potassium salt (297 mg, 1.0 mmol) in CH3CN (15 ml) and MeOH (1.5 ml) was added. After 3h IN HC1 (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). The organic layers were washed with brine (10 ml), dried over Na2SO4, filtered and concentrated to give the title compound as a white solid. 19F NMR of the product indicated a diastereomeric ratio of 1 1 : 1 . Zinc (II) chloride (204 mg, 1.5 mmol) and sodium borohydride (113 ing, 3.0 mmol) were suspended in DME (1.5 mL) and stirred for 18h. The resulting suspension was cooled to - 40 °C and a suspension of 7V-(2,2,2-trifluoro-l-phenylethylidene)-L-alinine potassium salt (283 mg, 1.0 mmol) in CH3CN (15 ml) and MeOH (1.5 ml) was added. After 3h IN HCI (20 ml) was added and the mixture was extracted with TBME (3 x 20 ml). 'Hie organic layers were washed with brine (10 ml), dried over Na2SC4, filtered and concentrated to give the title compound as a white solid, diastereorneric ratio of 6:1. A 200 mL vessel was charged with 2,2,2-trifluoro-l-[4'-(methylsulphonyl)biphenyl-4- yl]ethane-l,l-diol (9.08 g, 26.2 mmol), F-leucine ethyl ester sulphate salt (8.66 g, 31.5 mmol), potassium carbonate (14.5 g, 104.9 mmol) and methanol (27.3 mL). The mixture was heated to 50 °C, aged for 4 h and then cooled to -5 °C. A 500 mL vessel was charged with zinc chloride (7.15 g, 52.5 mmol) and dimethoxyethane (40.9 mL). The mixture was cooled to -10 °C and sodium borohydride (3.97 g, 104.9 mmol) charged in a portionwise manner. The mixture was aged at -10 °C for 1 h and acetonitrile (63.6 mL) added, maintaining the temperature below 0 °C. The imine mixture was then transferred to the borohydride solution, at such a rate as to maintain the temperature between -5 and +5 °C. The reaction was then aged between -5 and +5 °C for 1.5 h, quenched by the slow addition of acetone (33.9 mL) and allowed to warm to 20 °C. TBME (60.6 mL), 2M HCI (181.7 mL) and DI Water (63.6 mL) were charged and the mixture aged for 30 min. The organic phase was separated and the aqueous re-extracted with TBME (45.4 mL). The two TBME phases were combined, washed with water (45.4 mL x 4) and diluted with TBME (139.3 mL). Dicyclohexylaminc (5.23g, 28.8 mmol) was then charged over 30 min at 20 °C. The product slurry was aged at 20 °C for 1 h, filtered and washed with TBME (36.3 mL). After drying in-vacuo at 30 °C to constant weight, the title compound was obtained as a white powder. WE CLAIM: 1. A process for preparing a compound of formula LA or IB: comprising the steps of: a. Combining a ketone or ketal with an Daminoester of formula II in the presence of a base and solvent to form an imine metal carboxylate of formula III, and (Figure Removed) b. Reducing the imine metal carboxylate of formula HI to produce a compound of formula IA or IB; wherein Rl is Ci-5 alkyl, C3-g cycloalkyl, aryl or heteroaryl; R2 is C1-5 alkyl, C-5 haloalkyl, C3-g cycloalkyl, arylalkyl, aryl or heteroaryl; R3 Ci-5 alkyl, Ci-5 haloalkyl, C3-g cycloalkyl, aryl, heteroaryl, CF3, CHF2,CH2F or M is hydrogen, lithium, sodium, potassium or cesium. 2. The process of Claim 1 wherein the base is a metal carbonate or alkoxide, and the solvent is an alcohol, an ether, an ester or an amide. 3. The process of Claim 2 wherein the base is potassium carbonate, potassium methoxide or potassium phosphate and the solvent is methanol. 4. The process of Claim 1 wherein step a is performed at a temperature of about 15°C to about 80°C. 5. The process of Claim 4 wherein the temperature is about 30°C to about 60°C. 6. The process of Claim 1 wherein the imine metal carboxylate of formula III is not isolated, and the reduction is performed with a metal borohydride prepared in an ether solvent to yield a compound of formula IA. 7. The process of Claim 6 wherein the metal borohydride is calcium borohydride, magnesium borohydride, zinc borohydride or zirconium borohydride and the ether solvent is tetrahydrofuran, diethyl ether, diisopropyl ether, dibutyl ether, tbutylmethyl ether, dimethoxyethane, ethyleneglycoldimethyl ether or mixtures thereof. 8. The process of Claim 6 wherein a co-solvent is added in a volume of 50-95%. 9. The process of Claim 8 wherein the co-solvent is C 1.4 alkyl or aryl nitrile. 10. The process of Claim 1 wherein step b is performed at a temperature of about 25 to about-40°C. 11. An invention substantially such as herein before described.

Documents:

1689-delnp-2007-abstract.pdf

1689-DELNP-2007-Assignment.pdf

1689-delnp-2007-claims.pdf

1689-delnp-2007-Clams-(28-03-2013).pdf

1689-delnp-2007-Correspondence Others-(25-07-2008).pdf

1689-delnp-2007-Correspondence Others-(28-03-2013).pdf

1689-DELNP-2007-Correspondence-Others-(05-02-2013).pdf

1689-DELNP-2007-Correspondence-Others-(20-07-2010).pdf

1689-DELNP-2007-Correspondence-Others-(22-02-2013).pdf

1689-delnp-2007-correspondence-others.pdf

1689-delnp-2007-description (complete).pdf

1689-DELNP-2007-Form-1-(20-07-2010).pdf

1689-delnp-2007-form-1.pdf

1689-delnp-2007-Form-18-(25-07-2008).pdf

1689-DELNP-2007-Form-2-(20-07-2010).pdf

1689-delnp-2007-form-2.pdf

1689-DELNP-2007-Form-3-(20-07-2010).pdf

1689-delnp-2007-Form-3-(28-03-2013).pdf

1689-delnp-2007-form-3.pdf

1689-DELNP-2007-Form-5-(20-07-2010).pdf

1689-delnp-2007-form-5.pdf

1689-DELNP-2007-GPA-(05-02-2013).pdf

1689-DELNP-2007-GPA-(20-07-2010).pdf

1689-DELNP-2007-GPA-(22-02-2013).pdf

1689-delnp-2007-GPA-(28-03-2013).pdf

1689-delnp-2007-gpa.pdf

1689-delnp-2007-pct-101.pdf

1689-delnp-2007-pct-210.pdf

1689-delnp-2007-pct-220.pdf

1689-delnp-2007-pct-237.pdf

1689-delnp-2007-pct-311.pdf